AIM: To establish a kind of standardization of the clinical chemotherapeutic prototypes for unresectable hepatocellular carcinomas (HCC). METHODS: 10-Hydroxycamptothecin (HCPT) was applied through transcatheter arterial embolization (TAE) to HCC patients who were categorized into three groups: (1) test group: treatment with HCPT twice (HCPT d1 and 14) through TAE and portal venous embolization. (2) Control Ⅰ: treatment with anticancer drugs without HCPT. (3) Control Ⅱ: treatment with HCPT as a major component in anticancer drugs once (HCPT d1). A set of comparisons between test groups and control Ⅰ and Ⅱ groups were performed before and after the treatment to study the effectiveness of each treatment, in terms of tumor volumes, dynamic variations in serum alpha-fetoprotein (AFP), gamma-glutamyl transferase hepatoma-specific band (GGT-Ⅱ), patient survival and adverse events. RESULTS: The general effectiveness rate of the test group reached 62.1% (72/116), remarkably higher than that of control Ⅰ (32.1%, 40/124) and control Ⅱ (54.7%, 47/56), (P<0.01 and P<0.05, respectively). Especially, the reduction rate or disappearance of the portal vein tumor emboli was as high as 88.4% (61/69) in the test group, in contrast with 13.9% (10/72) in control Ⅰ and 35.9% (18/51) in control Ⅱ (P<0.01 and P<0.01, respectively). After treatment, AFP decreased or turned to negative levels at 52.3% (34/65) in control 1,67.3% (35/52) in control Ⅱ, and 96.8% (60/62) in the test group. Also GGT-II declined or became negative at 37.8% (28/74) in control Ⅰ, 69.5% (57/82) in control Ⅱ, and 94.7% (89/94) in test group (P<0.01 and P<0.05, respectively). CONCLUSION: We have designed a good protocol (test group) to treat HCC with excellent advantages of high efficiency, low cost, low toxicity and low adverse events and easy application. It could be recommended as one of the standardizations for HCC treatment in clinical practice. AIM: To establish a kind of standard of the clinical chemotherapeutic prototypes for unresectable hepatocellular carcinomas (HCC). METHODS: 10-Hydroxycamptothecin (HCPT) was applied through transcatheter arterial embolization (TAE) to HCC patients who were categorized into three groups: (1 (3) Control II: treatment with HCPT as a major component in anticancer drugs A set of comparisons between test groups and control I and II groups were performed before and after the treatment to study the effectiveness of each treatment, in terms of tumor volumes, dynamic variations in serum alpha-fetoprotein (AFP) RESULTS: The general effectiveness rate of the test group reached 62.1% (72/116), remarkably higher tha thai-specific band (GGT-II) n that of control Ⅰ (32.1%, 40/124) and control Ⅱ (54.7%, 47/56), respectively (P <0.01 and P <0.05, respectively). Especially, the reduction rate or disappearance of the portal vein tumor emboli were as high as 88.4% (61/69) in the test group, in contrast with 13.9% (10/72) in control I and 35.9% (18/51) in control II (P <0.01 and P <0.01, respectively After treatment, AFP decreased or turned to negative levels at 52.3% (34/65) in control 1, 67.3% (35/52) in control Ⅱ, and 96.8% (60/62) in the test group. Also GGT -II declined or became negative at 37.8% (28/74) in control Ⅰ, 69.5% (57/82) in control Ⅱ, and 94.7% (89/94) in test group (P <0.01 and P <0.05, respectively) CONCLUSION: We have designed a good protocol (test group) to treat HCC with excellent advantages of high efficiency, low cost, low toxicity and low adverse events and easy application. It could be recommended as one of the standardizations for HCC treatment in clinical practice.